X0306 4 2020-11-03 0 0001477449 Teladoc Health, Inc. TDOC 0001830520 Geshuri Arnnon C/O TELADOC HEALTH, INC. 2 MANHATTANVILLE ROAD, SUITE 203 PURCHASE NY 10577 0 1 0 0 Chief Human Resources Officer Common Stock 2020-11-03 4 A 0 78707 A 104743 D Employee Stock Option (right to buy) 2.73 2020-11-03 2017-12-14 4 A 0 239128 A 2027-12-03 Common Stock 239128 239128 D Employee Stock Option (right to buy) 5.26 2020-11-03 2018-06-19 4 A 0 34456 A 2028-06-18 Common Stock 34456 34456 D Reflects shares of common stock, par value $0.001 per share, of the Issuer ("Common Stock") underlying restricted stock units ("RSUs") acquired by the Reporting Person on October 30, 2020, upon completion of the merger (the "Merger") of Tempranillo Merger Sub, Inc., a wholly owned subsidiary of the Issuer, with and into Livongo Health, Inc. ("Livongo") pursuant to the Agreement and Plan of Merger, dated as of August 5, 2020 (the "Merger Agreement"), based on the Reporting Person's previously outstanding RSUs of Livongo multiplied by an equity award adjustment ratio of 0.6891 (rounded down to the nearest whole share), which was only determinable on November 3, 2020 in accordance with the Merger Agreement. The shares of Common Stock underlying the RSUs vest as follows: (1) 41,273 RSUs vest in 48 equal monthly installments beginning on January 15, 2019, although the vesting of these RSUs beginning in February 2020 was modified by Livongo such that the RSUs vest on the February 25, May 25, August 25 or November 25 that occurs immediately prior to applicable vesting date, and (ii) 23,688 and 13,746 RSUs vest in 16 equal quarterly installments beginning on August 25, 2019, and May 25, 2020, respectively. Includes shares of Livongo common stock acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan that were converted into 125 shares of Common Stock pursuant to the Merger Agreement. Reflects options acquired by the Reporting Person on October 30, 2020, upon completion of the Merger pursuant to the Merger Agreement, based on the Reporting Person's previously outstanding options of Livongo, multiplied by an equity award adjustment ratio of 0.6891 (rounded down to the nearest whole share), which was only determinable on November 3, 2020 in accordance with the Merger Agreement. Upon completion of the Merger, the exercise prices of the Reporting Person's options were adjusted based on the quotient of the exercise price of the Reporting Person's previously outstanding options of Livongo over an equity award adjustment ratio of 0.6891 (rounded up to the nearest whole cent), which was only determinable on November 3, 2020 in accordance with the Merger Agreement. One-fourth of the option vested on December 4, 2018 and 1/48 of the option vests monthly thereafter. One-fourth of the option vested on June 19, 2019 and 1/48 of the option vests monthly thereafter. /s/ Adam C. Vandervoort, as attorney-in-fact 2020-11-05